See more : HIRANO TECSEED Co.,Ltd. (6245.T) Income Statement Analysis – Financial Results
Complete financial analysis of Innate Pharma S.A. (IPHA) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Innate Pharma S.A., a leading company in the Biotechnology industry within the Healthcare sector.
- Gulfport Energy Corporation (GPOR) Income Statement Analysis – Financial Results
- Ablerex Electronics Co., Ltd. (3628.TWO) Income Statement Analysis – Financial Results
- LEG Immobilien SE (LEG.SW) Income Statement Analysis – Financial Results
- Spring Ventures Ltd (SPRG.TA) Income Statement Analysis – Financial Results
- Urja Global Limited (URJA.NS) Income Statement Analysis – Financial Results
Innate Pharma S.A. (IPHA)
About Innate Pharma S.A.
Innate Pharma S.A., a biotechnology company, discovers, develops, and commercializes therapeutic antibodies for the treatment of oncology indications in France and internationally. The company's products include Lacutamab (IPH4102), an anti-KIR3DL2 antibody, which is in Phase II clinical trials for the treatment of cutaneous T-cell and peripheral T-cell lymphoma, as well as in Phase II clinical trials to treat refractory sézary syndrome; Monalizumab, an immune checkpoint inhibitor that is in Phase III clinical trial to treat advanced solid tumors comprising colorectal and lung cancer, as well as head and neck cancer; Avdoralimab (IPH5401), a monoclonal antibody blocking C5a binding to C5aR1 that is in Phase II clinicals trials for the treatment of COVID-19, bullous pemphigoid, chronic spontaneous urticaria, and other inflammatory diseases; IPH5201, a blocking antibody that is in Phase 1 clinical trials targeting the CD39 immunosuppressive pathway; IPH5301, an anti-CD73 antibody targeting the immunosuppressive adenosine pathway to promote antitumor immunity; and IPH6101, a NKp46-based NK cell engager for the generation and evaluation of up to two bispecific NK cell engagers. Its products in preclinical trials are IPH43, an anti-MICA/B antibody drug conjugate; Anti-Siglec-9, an antibody program; IPH65, a tetraspecific proprietary antibody; IPH25, a checkpoint inhibitor; and IPH62 and IPH64 programs. Innate Pharma S.A. has licensing and collaboration agreements with AstraZeneca, Novo Nordisk A/S, Sanofi, and Orega Biotech; and co-development and license agreement with MedImmune Limited. The company was incorporated in 1999 and is headquartered in Marseille, France.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 51.90M | 49.64M | 12.11M | 56.83M | 68.97M | 79.89M | 32.63M | 56.16M | 17.91M | 907.00K | 12.47M | 10.38M | 11.74M | 4.32M | 7.72M | 12.92M | 14.29M | 6.20M | 1.30M |
| Cost of Revenue | 56.02M | 51.66M | 47.00M | 3.04M | 45.16M | 69.56M | 67.00M | 48.63M | 29.91M | 12.09M | 7.58M | 6.86M | 1.64M | 3.43M | 3.35M | 2.56M | 2.77M | 2.20M | 944.00K |
| Gross Profit | -4.12M | -2.02M | -34.89M | 53.79M | 23.82M | 10.34M | -34.37M | 7.53M | -12.00M | -11.18M | 4.89M | 3.51M | 10.10M | 893.00K | 4.37M | 10.37M | 11.52M | 3.99M | 356.00K |
| Gross Profit Ratio | -7.94% | -4.08% | -288.08% | 94.65% | 34.53% | 12.94% | -105.33% | 13.41% | -67.02% | -1,232.64% | 39.22% | 33.86% | 86.05% | 20.67% | 56.62% | 80.21% | 80.64% | 64.47% | 27.38% |
| Research & Development | 56.02M | 51.66M | 47.00M | 58.61M | 1.60M | 69.56M | 67.00M | 48.63M | 29.91M | 22.67M | 15.13M | 13.42M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 11.75M | 14.47M | 15.99M | 31.25M | 40.73M | 18.14M | 15.66M | 8.88M | 5.59M | 12.50M | 10.38M | 9.33M | 0.00 | 6.27M | 8.52M | 0.00 | 0.00 | 1.64M | 938.00K |
| Selling & Marketing | 0.00 | 7.96M | 9.53M | -861.00K | 8.85M | 1.11M | 527.00K | 450.00K | 288.00K | 314.00K | 283.00K | 406.00K | 9.79M | 7.06M | 10.06M | 0.00 | 0.00 | 207.00K | 139.00K |
| SG&A | 11.75M | 22.44M | 25.52M | 30.39M | 49.58M | 19.25M | 16.18M | 9.33M | 5.88M | 12.82M | 10.67M | 9.73M | 9.79M | 7.06M | 10.06M | 0.00 | 0.00 | 1.84M | 1.08M |
| Other Expenses | -3.20M | -8.04M | -12.59M | -13.62M | -309.00K | -14.06M | -10.57M | -9.37M | -7.11M | -19.00K | 179.00K | 2.00K | 7.88M | 32.00K | 909.00K | 21.37M | 20.62M | 9.34M | 5.69M |
| Operating Expenses | 64.57M | 66.06M | 59.94M | 75.38M | 50.87M | 74.75M | 72.61M | 48.59M | 28.68M | 8.76M | 7.66M | 6.88M | 17.67M | 14.58M | 19.90M | 21.37M | 20.62M | 11.18M | 6.77M |
| Cost & Expenses | 64.57M | 66.06M | 59.94M | 75.38M | 96.03M | 74.75M | 72.61M | 48.59M | 28.68M | 20.85M | 15.24M | 13.75M | 19.31M | 18.01M | 23.25M | 23.93M | 23.38M | 13.38M | 7.72M |
| Interest Income | 3.18M | 4.78M | 6.34M | 4.86M | 1.62M | 1.58M | 1.25M | 0.00 | 27.00K | 445.00K | 244.00K | 34.00K | 945.00K | 541.00K | 0.00 | 1.19M | 212.00K | 1.20M | 280.00K |
| Interest Expense | 640.00K | 5.32M | 4.00M | 6.76M | 204.00K | 102.00K | 113.00K | 124.00K | 139.00K | 0.00 | 0.00 | 225.00K | 520.00K | 509.00K | 0.00 | 36.00K | 39.00K | 2.00K | 0.00 |
| Depreciation & Amortization | 5.09M | 4.42M | 4.57M | 9.39M | 16.53M | 7.40M | 4.40M | 3.26M | 2.66M | 2.34M | 880.00K | 839.00K | 901.00K | 1.10M | 1.02M | 539.00K | 536.00K | 298.00K | 301.00K |
| EBITDA | -1.84M | -61.30M | -43.23M | 43.11M | -20.86M | -3.30M | -35.65M | 10.83M | -8.09M | -17.14M | -1.91M | -1.76M | -5.80M | -12.32M | -14.47M | -12.48M | -8.50M | -6.94M | -6.11M |
| EBITDA Ratio | -3.54% | 68.00% | -304.53% | 75.85% | -12.88% | 15.48% | -109.25% | 20.73% | -45.18% | -1,967.81% | -17.70% | -27.62% | -47.19% | -291.44% | -187.48% | -80.99% | -59.51% | -91.90% | -448.31% |
| Operating Income | -12.67M | -11.65M | -47.83M | -13.69M | -27.05M | 5.15M | -39.98M | 7.57M | -10.77M | -19.97M | -2.79M | -3.39M | -7.57M | -13.69M | -15.54M | -11.01M | -9.09M | -7.24M | -6.42M |
| Operating Income Ratio | -24.41% | -23.47% | -394.86% | -24.09% | -39.22% | 6.44% | -122.53% | 13.48% | -60.16% | -2,201.32% | -22.40% | -32.63% | -64.48% | -316.90% | -201.33% | -85.16% | -63.62% | -116.85% | -493.46% |
| Total Other Income/Expenses | 5.10M | -547.00K | 2.35M | -15.53M | 6.29M | -2.43M | -8.03M | 5.37M | 4.07M | 319.00K | -99.00K | 183.00K | 590.00K | 32.00K | 909.00K | 1.15M | 173.00K | 1.20M | 286.00K |
| Income Before Tax | -7.57M | -57.97M | -45.48M | -63.98M | -20.76M | 2.72M | -48.02M | 12.94M | -6.71M | -19.65M | -2.89M | -3.20M | -6.98M | -13.66M | -14.63M | -9.85M | -8.92M | -6.04M | -6.13M |
| Income Before Tax Ratio | -14.59% | -116.79% | -375.48% | -112.58% | -30.10% | 3.40% | -147.15% | 23.04% | -37.45% | -2,166.15% | -23.19% | -30.83% | -59.45% | -316.16% | -189.55% | -76.23% | -62.41% | -97.53% | -471.46% |
| Income Tax Expense | 0.00 | 41.13M | 13.66M | 6.76M | 206.00K | -333.00K | 368.00K | 301.00K | 139.00K | -24.00K | -51.00K | -146.00K | 1.13M | 0.00 | 46.00K | 0.00 | 51.00K | 1.20M | 286.00K |
| Net Income | -7.57M | -99.10M | -59.14M | -70.75M | -20.97M | 3.05M | -48.39M | 12.64M | -6.71M | -19.65M | -2.89M | -3.20M | -6.98M | -13.66M | -14.63M | -9.85M | -8.92M | -6.04M | -6.13M |
| Net Income Ratio | -14.59% | -199.65% | -488.24% | -124.48% | -30.40% | 3.82% | -148.28% | 22.51% | -37.45% | -2,166.15% | -23.19% | -30.83% | -59.45% | -316.16% | -189.55% | -76.23% | -62.41% | -97.53% | -471.46% |
| EPS | -0.09 | -1.24 | -0.74 | -0.90 | -0.31 | 0.05 | -0.89 | 0.23 | -0.13 | -0.39 | -0.07 | -0.08 | -0.19 | -0.36 | -0.56 | -0.38 | -0.36 | -0.34 | -0.41 |
| EPS Diluted | -0.09 | -1.24 | -0.74 | -0.90 | -0.31 | 0.05 | -0.89 | 0.23 | -0.13 | -0.39 | -0.07 | -0.08 | -0.19 | -0.36 | -0.56 | -0.38 | -0.36 | -0.34 | -0.41 |
| Weighted Avg Shares Out | 80.45M | 79.64M | 79.54M | 78.93M | 66.91M | 58.78M | 54.35M | 53.87M | 51.58M | 50.15M | 38.70M | 37.80M | 37.69M | 37.44M | 26.30M | 25.67M | 25.08M | 17.77M | 14.90M |
| Weighted Avg Shares Out (Dil) | 80.45M | 79.64M | 79.54M | 78.93M | 66.91M | 58.78M | 54.35M | 53.87M | 53.40M | 50.15M | 38.70M | 37.80M | 37.69M | 37.44M | 26.30M | 25.67M | 25.08M | 17.77M | 14.90M |
Innate Pharma Announces Publication of Preclinical Data with a Trifunctional NK Cell Engager in Acute Myeloid Leukemia in Nature Biotechnology
Penny Stocks To Buy Now? 6 To Watch With Big News Today
Press Release: Sanofi and Innate Pharma expand collaboration for natural killer cell therapeutics in oncology
Sanofi and Innate Pharma Expand Collaboration for Natural Killer Cell Therapeutics in Oncology
Innate Pharma Presents Data From Ongoing Phase 2 TELLOMAK Trial Demonstrating Clinical Activity of Lacutamab in Advanced Sézary Syndrome at ASH 2022
Innate Pharma S.A. (IPHA) Q3 2022 Earnings Call Transcript
Innate Pharma Reports Third Quarter Financial Results
Innate Pharma Announces Conference Call and Webcast for Third Quarter 2022 Business Update
Innate Pharma to Present Results From a Preliminary Analysis of the TELLOMAK Phase 2 Trial in Patients With Advanced Sezary Syndrome and ANKET™ Platform at ASH 2022
Innate Pharma to Participate in Upcoming Investor Conferences
Source: https://incomestatements.info
Category: Stock Reports